Neurotrophic keratopathy: current challenges and future prospects.
NaPier E, Camacho M, McDevitt TF, Sweeney AR.
Ann Med. 2022 Dec;54(1):666-673. doi: 10.1080/07853890.2022.2045035.
PMID:35243932
Cenegermin (Oxervate): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
[No authors listed]
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.
PMID:38723125
PERSISTENT CORNEAL EPITHELIAL DEFECT AFTER PARS PLANA VITRECTOMY.